P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.
Conflict of interest: No Introduction and Objectives: There is increasing evidence that a ≥20% decrease in sequential liver stiffness measurements (ΔLSM) by transient elastography (TE) is associated with a lower risk of long-term liver-related outcomes and mortality in patients with MASLD. Objective...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268124004009 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Conflict of interest: No Introduction and Objectives: There is increasing evidence that a ≥20% decrease in sequential liver stiffness measurements (ΔLSM) by transient elastography (TE) is associated with a lower risk of long-term liver-related outcomes and mortality in patients with MASLD. Objective: We aimed to evaluate factors associated with ≥20% decrease in ΔLSM in MASLD patients with prediabetes (Pre-DM) and type 2 diabetes (T2DM). Patients / Materials and Methods: MASLD adults with PreDM or T2DM with two consecutive reliable LSMs by transient TE (Fibroscan Touch 502) were included. Clinical, biochemical and elastography data were collected at baseline and follow-up. PNPLA3 (rs738409 C>G) genotypes were determined. A multivariate logistic regression analysis was performed to evaluate the variables independently associated with ≥20% decrease in ΔLSM. All data were analyzed using the statistical package SPSS (vs.24.0,IBM), a p-value < 0.05 was regarded as significant. Results and Discussion: 294 patients were included (70% female, 60 ± 10 y, 63% with BMI ≥ 30 kg/m2): 14% had PreDM and 86% T2DM. Genotyping of PNPLA3 was identified as CC in 46% and CG+GG in 54%. At the first TE, 10% had LSM > 15kPa [median 7.0 kPa (5.1-10.1)]. Overall, 31% experienced a ≥20% decrease in ΔLSM on a 38 (26-52) months interval.On logistic multivariate regression, the variables independently associated with a ≥20% decrease in ΔLSM were the genotype CC of PNPLA3 (OR 1.71/ 95%CI 1.03-2.85; p=0.038) and final glycated hemoglobin ≤7% (OR 1.75/ 95%CI 1.04-2.94; p=0.034) . Statin use (OR 1.78/ 95%CI 0.99-3.18; p=0.05) had a borderline statistical significance. Conclusions: A clinically significant improvement in LSM is associated with a better glycemic control and the presence of wild-type PNPLA3CC in MASLD patients with PreDM or T2DM. Future prospective studies are needed to determine whether genetic predisposition and factors of clinical importance may confer a reduction in the risk of liver-related outcomes in these high-risk populations. |
|---|---|
| ISSN: | 1665-2681 |